Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

Key Inclusion Criteria:

• 12 years to < 18 years of age at baseline

• Able to give written assent prior to any screening evaluations

• Parent or guardian able to give written informed consent prior to any screeningevaluations and willing to comply with study requirements

• Plasma HIV-1 RNA levels of ≥ 1,000 copies/mL

• CD4+ cell count > 100 cells/µL

• Weight ≥ 35 kg (77 lbs)

• Screening genotype report must show sensitivity to FTC and TDF

• Able to swallow oral tablets

• Adequate renal function

• Clinically normal ECG

• Documented screening for active pulmonary tuberculosis per local standard of carewithin 6 months of a screening visit

• Hepatic transaminases ≤ 5 x upper limit of normal

• Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

• Individuals with a positive Hepatitis B surface antigen screening test can participatein the study, providing that alternate therapy (other than TDF) for chronic HepatitisB infection is available as a part of local standard of care

• Adequate hematologic function

• Negative serum pregnancy test for all females

• Males and females of childbearing potential must agree to utilize highly effectivecontraception methods while on study treatment or agree to abstain from heterosexualintercourse throughout the study period and for 30 days following the last dose ofstudy drug

• Males must agree to utilize a highly effective method of contraception duringheterosexual intercourse throughout the study period and for 30 days followingdiscontinuation of investigational medicinal product

• Must be willing and able to comply with all study requirements

• Life expectancy ≥ 1 year

Key Exclusion Criteria:

• A new AIDS-defining condition diagnosed within the 30 days prior to screening

• Prior treatment with any approved or investigational or experimental anti HIV-1 drugfor any length of time (other than that given for prevention of mother-to-childtransmission)

• Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 monthsof the screening visit

• Anticipated to require rifamycin treatment for mycobacterial infection whileparticipating in the study. Note: prophylactic Isoniazid (INH) therapy for latenttuberculosis (TB) treatment is allowed.

• Individuals experiencing decompensated cirrhosis

• Pregnant or lactating females

• Have any serious or active medical or psychiatric illness which would interfere withtreatment, assessment, or compliance with the protocol. This would includeuncontrolled renal, cardiac, hematological, hepatic, pulmonary, endocrine, centralnervous, gastrointestinal, vascular, metabolic, immunodeficiency disorders, activeinfection, or malignancy that are clinically significant or requiring treatment within 30 days prior to the study dosing.

• Current alcohol or substance abuse that will potentially interfere with compliance

• Have history of significant drug sensitivity or drug allergy

• Known hypersensitivity to the study drugs, the metabolites or formulation excipients

• Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3months of study screening or expected to receive these agents during the study

• A history of malignancy within the past 5 years or ongoing malignancy other thancutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneoussquamous carcinoma

• Have previously participated in an investigational trial involving administration ofany investigational agent within 30 days prior to the study dosing

• Participation in any other clinical trial without prior approval from sponsor isprohibited while participating in this trial

• Receiving ongoing therapy with any disallowed medications, including drugs not to beused with EVG, COBI, FTC, TDF or individuals with any known allergies to theexcipients of EVG/COBI/FTC/TDF STR tablets Note: Other protocol defined Inclusion/Exclusion criteria may apply.